NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
Clinical Trials
42 trialsNCT02687958 2023-05-30
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Unknown
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05124431 2021-11-18
ALTER-UC-001
Fudan University
Phase 2 Unknown
NCT01263951 2021-10-26
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Thomas Jefferson University
Phase 2 Unknown
NCT02294006 2021-09-09
MetNET1
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02695459 2021-04-20
Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
The Netherlands Cancer Institute
Phase 2 Unknown
NCT03095040 2021-02-08
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
AnewPharma
Phase 3 Unknown
NCT04212702 2021-01-12
ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments
National Taiwan University Hospital
Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT02109913 2019-10-14
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Amsterdam UMC, location VUmc
Phase NA Unknown
NCT03629847 2018-08-14
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
King Faisal Specialist Hospital & Research Center
Phase 1/2 Unknown
NCT02233049 2018-07-23
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT00499603 2016-11-01
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Unknown
NCT02013089 2016-08-30
GITIC
Sun Yat-sen University
Phase NA Unknown
NCT02404051 2016-06-15
FEVEX
Consorzio Oncotech
Phase 3 Unknown
NCT02616848 2015-11-30
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
Istituti Ospitalieri di Cremona
Phase 1 Unknown
NCT02188550 2015-05-19
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Sinai Hospital of Baltimore
Phase 2 Unknown
NCT01730209 2015-05-05
RAPIT
Erasmus Medical Center
Phase 2/3 Unknown
NCT02208128 2014-08-04
MORE
Heidelberg University
Phase NA Unknown
NCT02025712 2014-01-01
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
Organisation for Oncology and Translational Research
Phase 2 Unknown
NCT00544999 2013-09-17
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Unknown
NCT01932177 2013-08-30
EVESOR
Hospices Civils de Lyon
Phase 1 Unknown
NCT01118065 2013-08-12
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01216826 2013-08-07
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
Hospital Santa Marcelina
Phase 2 Unknown
NCT01216839 2013-03-26
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
Hospital Santa Marcelina
Phase 2 Unknown
NCT00636922 2013-02-15
Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
Bayside Health
Phase 1 Unknown
NCT00466102 2012-08-30
RADAR
GBG Forschungs GmbH
Phase 2 Unknown
NCT01423708 2012-07-18
EPOCAL
Azienda Ospedaliera di Padova
Phase 2 Unknown
NCT01088893 2012-05-24
Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy
Organisation for Oncology and Translational Research
Phase 2 Unknown
NCT01167530 2012-04-04
RAD001
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Unknown
NCT01525719 2012-02-03
CRAD001T
Ratchavithi Hospital
Phase 2 Unknown
NCT00930475 2011-01-26
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer
Charite University, Berlin, Germany
Phase 1/2 Unknown
NCT01175096 2010-08-04
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Guangdong Provincial People's Hospital
Phase 1/2 Unknown
NCT00973713 2009-09-09
RADiChol
Austin Health
Phase 2 Unknown
NCT00390195 2009-07-02
Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 1/2 Unknown
NCT00903188 2009-05-18
CISTCERT
University Hospital, Antwerp
Phase 4 Unknown
NCT00657982 2009-01-21
Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer
Sheba Medical Center
Phase 2 Unknown